pneumonia%20-%20community-acquired
PNEUMONIA - COMMUNITY-ACQUIRED
Community-Acquired Pneumonia (CAP) is an acute infection of the pulmonary parenchyma accompanied by symptoms of acute illness and abnormal chest findings.
It is a lower respiratory tract infection acquired in the community within 24 hours to <2 weeks or occurring ≤48 hours of hospital admission in patients who do not meet the criteria for healthcare-associated pneumonia.
It occurs at the highest rates in the very young and the very old.
Potentially life-threatening especially in older adults and those with comorbid disease.
Drug Information

Indication: Short-term treatment of upper & lower resp tract, skin & soft tissue, GUT infections. Tab & inj Sh...

Indication: Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired & nosoco...

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Infections of the resp tract, middle ear (otitis media), paranasal sinuses (sinusitis) especially caused by gm...

Indication: Active immunisation for the prevention of pneumococcal disease caused by Strep pneumoniae serotypes 1, 3, 4, 5...

Indication: Upper & lower resp tract infection, upper & lower UTI, peritonitis, cholecystitis, cholangitis & o...

Indication: Lower resp tract, complicated & uncomplicated UTI, intra-abdominal, skin & skin structure infections; ...

Indication: Complicated skin & skin structure infections, complicated intra-abdominal infections (cIAI) in adults.

Indication: Upper & lower resp tract infections including sinusitis, otitis media & epiglottitis, bacterial pneumo...

Indication: Active immunisation of adults & childn ≥6 mth for prevention of influenza disease caused by 2 influenza...

1  /  26
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).